New treatment lenebasum shows promise for diffuse cutaneous systemic sclerosis (dcSSc)

(European League Against Rheumatism) The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis (dcSSc) with no severe or serious adverse events (AE).